COMMON STOCK PURCHASE WARRANT CONTRAVIR PHARMACEUTICALS, INC.Hepion Pharmaceuticals, Inc. • November 12th, 2020 • Pharmaceutical preparations
Company FiledNovember 12th, 2020 IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the six month anniversary of the Original Issue Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 14, 2023 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ContraVir Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO NICAMS PURCHASE AND SALE AGREEMENT May 26, 2016Nicams Purchase and Sale Agreement • November 12th, 2020 • Hepion Pharmaceuticals, Inc. • Pharmaceutical preparations • British Columbia
Contract Type FiledNovember 12th, 2020 Company Industry JurisdictionTHIS AMENDMENT NO. 1 (this “Amendment”) to the NCIAMs Purchase and Sale Agreement, is made and entered into as of May 26, 2016, by and between Aurinia Pharmaceuticals Inc., a Canadian corporation (“Aurinia”), Ciclofilin Pharmaceuticals Corp., an Alberta corporation (“CPC”), and Ciclofilin Pharmaceuticals, Inc., a Delaware corporation as successor in interest to Ciclofilin Pharmaceuticals Inc., a California corporation (“CPI”). Aurinia, CPI and CPC may each be referred to herein individually as a “Party” and collectively as the “Parties”.
NICAMs Purchase and Sale Agreement by and between Ciclofilin Pharmaceuticals Corp. and Aurinia Pharmaceuticals Inc. February 14, 2014 NICAMs Purchase and Sale Agreement Summary of ContentsPurchase and Sale Agreement • November 12th, 2020 • Hepion Pharmaceuticals, Inc. • Pharmaceutical preparations • British Columbia
Contract Type FiledNovember 12th, 2020 Company Industry JurisdictionThis NICAMs Purchase and Sale Agreement (the “Agreement”) dated February 14, 2014 (the “Effective Date”) by and between Aurinia Pharmaceuticals Inc., a Canadian corporation with an office at #1203 - 4464 Markham Street, Victoria, BC V8Z 7X8 Canada (“Aurinia”) and Ciclofilin Pharmaceuticals Corp., an Alberta corporation with an address at 34 Westbrook Drive, Edmonton, Alberta T6J 2C9 Canada (“CPC”), and Ciclofilin Pharmaceuticals Inc., a California corporation with an address at 3525 Del Mar Heights Road, Suite 427, San Diego, CA, USA 92130 (“CPI”). Aurinia, CPI and CPC may each be referred to herein individually as a “Party” and collectively as the “Parties”.